Conversely, FXR activation can ameliorate steatohepatitis and fibrosis by dynamically regulating lipid and glucose homeostasis in the NASH liver through cytokine-mediated mechanisms (Fiorucci et al., 2020). Here, NR1H4 is linked to metabolic dysfunction-associated steatohepatitis.